Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents

被引:357
作者
Dinarvand, R. [1 ,2 ]
Sepehri, N. [1 ]
Manoochehri, S. [1 ]
Rouhani, H. [1 ]
Atyabi, F. [1 ,2 ]
机构
[1] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut, Tehran, Iran
[2] Univ Tehran Med Sci, Nanotechnol Res Ctr, Tehran, Iran
关键词
nanotechnology; polymeric nanocarriers; targeting; anticancer agents; surface modification; LOADED PLGA NANOPARTICLES; LIPOSOMAL DOXORUBICIN DOXIL; IN-VIVO BIODISTRIBUTION; TARGETING CANCER-CELLS; DRUG-DELIVERY; BIODEGRADABLE NANOPARTICLES; CONTROLLED-RELEASE; PARTICLE-SIZE; POLY(D; L-LACTIDE-CO-GLYCOLIDE); NANOPARTICLES; POLY(DL-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES;
D O I
10.2147/IJN.S18905
中图分类号
TB3 [工程材料学];
学科分类号
082905 [生物质能源与材料];
摘要
The effectiveness of anticancer agents may be hindered by low solubility in water, poor permeability, and high efflux from cells. Nanomaterials have been used to enable drug delivery with lower toxicity to healthy cells and enhanced drug delivery to tumor cells. Different nanoparticles have been developed using different polymers with or without surface modification to target tumor cells both passively and/or actively. Polylactide-co-glycolide (PLGA), a biodegradable polyester approved for human use, has been used extensively. Here we report on recent developments concerning PLGA nanoparticles prepared for cancer treatment. We review the methods used for the preparation and characterization of PLGA nanoparticles and their applications in the delivery of a number of active agents. Increasing experience in the field of preparation, characterization, and in vivo application of PLGA nanoparticles has provided the necessary momentum for promising future use of these agents in cancer treatment, with higher efficacy and fewer side effects.
引用
收藏
页码:877 / 895
页数:19
相关论文
共 157 条
[1]
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy [J].
Acharya, Sarbari ;
Dilnawaz, Fahima ;
Sahoo, Sanjeeb K. .
BIOMATERIALS, 2009, 30 (29) :5737-5750
[2]
Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[3]
ALLEMANN E, 1993, EUR J PHARM BIOPHARM, V39, P173
[4]
Design and production of nanoparticles formulated from nano-emulsion templates-A review [J].
Anton, Nicolas ;
Benoit, Jean-Pierre ;
Saulnier, Patrick .
Journal of Controlled Release, 2008, 128 (03) :185-199
[5]
Synthesis and characterization of PLGA nanoparticles [J].
Astete, Carlos E. ;
Sabliov, Cristina M. .
JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, 2006, 17 (03) :247-289
[6]
Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid polyglycolic acid copolymers [J].
Athanasiou, KA ;
Niederauer, GG ;
Agrawal, CM .
BIOMATERIALS, 1996, 17 (02) :93-102
[7]
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in Vivo drug residence in blood properties [J].
Avgoustakis, K ;
Beletsi, A ;
Panagi, Z ;
Klepetsanis, P ;
Karydas, AG ;
Ithakissios, DS .
JOURNAL OF CONTROLLED RELEASE, 2002, 79 (1-3) :123-135
[8]
PLGA nanoparticles in drug delivery: The state of the art [J].
Bala, I ;
Hariharan, S ;
Kumar, MNVR .
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS, 2004, 21 (05) :387-422
[9]
Barratt, 2000, Pharm Sci Technol Today, V3, P163
[10]
Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation:: preparation, characterization and in vitro evaluation [J].
Betancourt, Tania ;
Brown, Brandon ;
Brannon-Peppas, Lisa .
NANOMEDICINE, 2007, 2 (02) :219-232